Margetuximab

Drug Profile

Margetuximab

Alternative Names: Anti-HER2-monoclonal-antibody-Green-Cross; MGAH-22

Latest Information Update: 04 May 2017

Price : $50

At a glance

  • Originator Raven biotechnologies
  • Developer Green Cross; MacroGenics; Merck Sharp & Dohme
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase I/II Gastric cancer
  • Phase I Bladder cancer; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 27 Apr 2017 MacroGenics initiates an expanded access for Breast cancer (Metastatic disease) in USA (NCT03133988)
  • 01 Jan 2016 Phase-I/II clinical trials in Gastric cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02689284)
  • 16 Dec 2015 Phase-III clinical trials in Breast cancer (Combination therapy, Second-line therapy or greater) in Germany, Portugal, Spain (IV) (EudraCT2015-000380-13)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top